Trulicity (dulaglutide) Another GLP-1 agonist, Trulicity, is approved for type 2 diabetes management
For Zepbound's 10mg weekly dose, the average weight loss was 22.2 kg (48.9 lb), and for Zepbound's 15mg weekly dose average weight loss was 23.6 kg (52.0 lb) over 72 weeks
Retatrutide is a triple receptor agonist that targets the GIP, GLP-1, and glucagon receptors
Retatrutide is currently under investigation in a global phase 3 clinical trial programme, following promising results from its phase 2 study (NCT04881760) published in the New England Journal of Medicine in 2023
For diabetes management under the Mounjaro brand, the medication is approved for adults with type 2 diabetes, in combination with diet and exercise
Aim for seven to nine hours of consistent sleep to allow your body to replenish its antioxidant stores and repair cellular damage in the hair follicles